Latest blog articles
-
Sometimes cases come along in which several unusual suspects come together. JF v EUCAP Somalia (T-194/20), for which the notification was published last Monday in the Official Journal, is one of them. In this case, a British national’s contract with the Common Security and Defence Policy (CSDP)...
-
How do we guarantee access to COVID-19 vaccines and therapies, and secure health-related human rights for all? We’ve heard a string of promises in the race for new vaccines and therapies.
-
During the corona crisis, national measures in the three countries on the Limburg borders are not coordinated equally well. As a result, there is currently a situation in the border region where certain border entrepreneurs fall between the cracks, such as in the Dutch newspaper NRC on April 2nd ("E...
-
During the Easter weekend there was a lack of clarity about what the rules are at the German-Dutch border. What is actually still allowed when it comes to travelling from the Netherlands to Germany and vice versa? Both the government in North Rhine-Westphalia (NRW) and in the Netherlands have...
-
It’s been almost a month since the COVID-19 pandemic has drastically changed the way we live and work. Now that we are more used to, in a manner of speaking, the extraordinary measures to curtail the rampant spread of the virus, it’s time to seriously consider, and openly discuss, this crisis’...
-
Cross-border non-coordination
Yesterday I was in Maastricht at the Belgian border which is no more than 1 km behind my house. I wanted to see it with my own eyes: the border was closed. The Belgian government has put up barriers to prevent us from entering their country. For five years we at ITEM... -
When the three main institutions adopted the Common Approach on EU Decentralised Agencies in 2012 one of the few innovative elements in this otherwise disappointing non-binding interinstitutional agreement were the provisions dedicated to the selection of the seat of EU agencies. As many EU-watchers...
-
Globally the majority of health-related R&D is invested in medicines with substantial guaranteed returns, yet what is missing is extensive R&D targeted at diseases overwhelmingly prevalent in developing countries. This threatens long-term availability of medicines and treatment options for these...